# Study of the Efficacy and Safety of Intravitreal (IVT) Aflibercept for the Improvement of Moderately Severe to Severe Nonproliferative Diabetic Retinopathy (NPDR)

> **NCT02718326** · PHASE3 · COMPLETED · sponsor: **Regeneron Pharmaceuticals** · enrollment: 402 (actual)

## Conditions studied

- Nonproliferative Diabetic Retinopathy

## Interventions

- **DRUG:** Intravitreal aflibercept injection [IAI]
- **DRUG:** Sham

## Key facts

- **NCT ID:** NCT02718326
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-03-29
- **Primary completion:** 2018-08-06
- **Final completion:** 2019-07-16
- **Target enrollment:** 402 (ACTUAL)
- **Last updated:** 2020-07-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02718326

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02718326, "Study of the Efficacy and Safety of Intravitreal (IVT) Aflibercept for the Improvement of Moderately Severe to Severe Nonproliferative Diabetic Retinopathy (NPDR)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02718326. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*